Format

Send to

Choose Destination
Methods Mol Biol. 2019;2029:215-234. doi: 10.1007/978-1-4939-9631-5_17.

Bone Marrow-Derived Progenitor Cells Mediate Immune Cell Regulation.

Author information

1
Faculty of Health and Medical Sciences, School of Medicine, University of Adelaide, Adelaide, SA, Australia. kisha.sivanathan@adelaide.edu.au.
2
Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA. kisha.sivanathan@adelaide.edu.au.
3
Faculty of Health and Medical Sciences, School of Medicine, University of Adelaide, Adelaide, SA, Australia.
4
Central Northern Adelaide Renal Transplantation Service, Royal Adelaide Hospital, Adelaide, SA, Australia.

Abstract

Human bone marrow (BM) derived mesenchymal stem cells (MSC) have high capacity to propagate ex vivo with superior reparative, immunosuppressive, and anti-inflammatory properties. Here we describe standardized protocols and culture conditions that enable the isolation, expansion and maintenance of a highly purified and homogenous population of human MSC. These third party-derived off-the-shelf MSC from healthy human bone marrow donors can potently inhibit mitogenically or allogeneically activated human T cells in proliferation assays. The standard operating procedures described in this chapter can be applied to researchers aiming to enhance MSC immunosuppressive properties and defining MSC mechanisms of action. Importantly, these assays can be incorporated into clinical protocols where the safety and efficacy of human BM MSC can be verified in diseases that are modulated by T cell responses.

KEYWORDS:

Bone marrow; Differentiation; Immunophenotyping; Mesenchymal stem cells; Mitogen; Mixed lymphocyte reactions; Peripheral blood mononuclear cells; Proliferation assays; T cells

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center